May 2024 | Report Format: Electronic (PDF)
Atopic Dermatitis Drugs Market Growth & Trends
The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.4% from 2023 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.
A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.
Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.’s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.
An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.
The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.
Request a free sample copy or view report summary:
Atopic Dermatitis Drugs Market Report
Atopic Dermatitis Drugs Market Report Highlights
- In 2022, biologics dominated the market owing to their higher demand and rising biologics approvals
- The injectable route of administration segment held the largest share in 2022 and is likely to maintain its dominance throughout the forecast period
- North America dominated the market in 2022 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region
Atopic Dermatitis Drugs Market Segmentation
Grand View Research has segmented the global atopic dermatitis drugs market report based on drug class, route of administration, and region:
Atopic Dermatitis Drugs Class Outlook (Revenue, USD Million, 2018–2030)
- Corticosteroids
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Biologics
- Others
Atopic Dermatitis Drugs Route of Administration Outlook (Revenue, USD Million, 2018–2030)
- Topical
- Injectable
- Oral
List of Key Players in Atopic Dermatitis Drugs Market
- Pfizer Inc.
- Sanofi
- AbbVie Inc.
- GALDERMA LABORATORIES, L.P.
- Eli Lilly and Company (Dermira)
- Regeneron Pharmaceuticals Inc.
- LEO Pharma Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Novartis AG
- Incyte Corporation
